Pejman Radkani

Dr. Pejman Radkani


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Dimitrios MorisDimitrios Moris
Dimitrios Moris
ILIoannis Liapis
Ioannis Liapis
PGPiyush Gupta
Piyush Gupta
IZIoannis A. Ziogas
Ioannis A. Ziogas
GKGeorgia-Sofia Karachaliou
Georgia-Sofia Karachaliou
PRPejman Radkani
Pejman Radkani
Currently, there is no reliable method of discerning between low-risk and high-risk intraductal papillary mucinous neoplasms (IPMNs). Operative resection is utilized in an effort to resect those lesions with high-grade dysplasia (HGD) prior to the development of invasive disease. The current guidelines recommend resection for IPMN that involve the main pancreatic duct. Resecting lesions with HGD before their progression to invasive disease and the avoidance of resection in those patients with low-grade dysplasia is the optimal clinical scenario. Therefore, the importance of developing preoperative models able to discern HGD in IPMN patients cannot be overstated. Low-risk patients should be managed with nonsurgical treatment options (typically MRI surveillance), while high-risk patients would undergo resection, hopefully prior to the formation of invasive disease. Current research is evolving in multiple directions. First, there is an ongoing effort to identify reliable markers for predicting malignant transformation of IPMN, mainly focusing on genomic and transcriptomic data from blood, tissue, and cystic fluid. Also, multimodal models of combining biomarkers with clinical and radiographic data seem promising for providing robust and accurate answers of risk levels for IPMN patients.

25 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
RGraffaelle girlanda
raffaelle girlanda
JLJedson R. Liggett
Jedson R. Liggett
MJMeth Jayatilake
Meth Jayatilake
AKAlexander Kroemer
Alexander Kroemer
JGJuan Francisco Guerra
Juan Francisco Guerra
TFThomas M. Fishbein
Thomas M. Fishbein
We analyzed the fecal microbiome by deep sequencing of the 16S ribosomal genes and the metabolomic profiles of 43 intestinal transplant recipients to identify biomarkers of graft function. Stool samples were collected from 23 patients with stable graft function five years or longer after transplant, 15 stable recipients one-year post-transplant and four recipients with refractory rejection and graft loss within one-year post-transplant. Lactobacillus and Streptococcus species were predominant in patients with stable graft function both in the short and long term, with a microbiome profile consistent with the general population. Conversely, Enterococcus species were predominant in patients with refractory rejection as compared to the general population, indicating profound dysbiosis in the context of graft dysfunction. Metabolomic analysis demonstrated significant differences between the three groups, with several metabolites in rejecting recipients clustering as a distinct set. Our study suggests that the bacterial microbiome profile of stable intestinal transplants is similar to the general population, supporting further application of this non-invasive approach to identify biomarkers of intestinal graft function.

13 February 2024 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
NLNicole Libbey
Nicole Libbey
LGLindsey Gallagher
Lindsey Gallagher
JCJonathan Cantalino
Jonathan Cantalino
BWBenjamin A. Weinberg
Benjamin A. Weinberg
MNMarcus S. Noel
Marcus S. Noel
KUKeith R. Unger
Keith R. Unger